Compound class:
Peptide
Comment: Blisibimod is a peptibody fusion containing four BAFF binding domains fused to a human Fc domain. By sequestering circulating BAFF ligand, it acts as a functional antagonist of BAFF interaction with the TACI receptor on B cells.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for blisibimod is claimed in Amgen's patent WO2002092620 [5]. |
For advanced searching click here to open chemical structure editor
Other Similar Sequences  |
|
| aflibercept |
Targetsnull |
| atacicept | |
| telitacicept |
Targetsnull |
